Drug/Small Molecule:
hydrochlorothiazide

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with hydrochlorothiazide that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105154

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs1007869 41231118C>T, 87616919C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1008899 -242+29754G>A, -320+29754G>A, -360G>A, 122+29754G>A, 156238G>A, 3653711G>A, 55862847G>A, 98+29754G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs1042713 148206440G>A, 148206440G>G, 46A>A, 46A>G, 46G>A, 5285A>A, 5285A>G, 9369367G>A, 9369367G>G, ADRB2:16Arg>Gly, ADRB2:Arg16Gly, ADRB2:Gly16Arg, Arg16, Arg16=
G > A
Missense
Arg16Gly
No VIP available No Clinical Annotations available VA
rs10497338 169084504T>C, 19293922T>C, 208+19234A>G
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs10792367 62758799C>G, 8064594C>G
C > G
Not Available
No VIP available No Clinical Annotations available VA
rs10845697 13184886G>A, 5945010G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs11135740 11225903G>A, 23367757G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs11240688 204134522G>A, 55623164G>A, 5944C>T, 98+802C>T
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs1159744 77621C>G, 874845C>G, 933-1363C>G, 934845C>G
C > G
Intronic
No VIP available CA VA
rs11600347 -192+3104G>T, -192+3754G>T, -22+3754G>T, 128733314C>A, 30+3104G>T, 32295730C>A, 8955G>T
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs11763492 1136637G>A, 1349-52144G>A, 146945089G>A, 7540712G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs12279250 1646-16656T>C, 1786+9019T>C, 21505079T>C, 21565079T>C
T > C
Intronic
No VIP available CA VA
rs12795437 -192+5542C>G, -192+6192C>G, -22+6192C>G, 11393C>G, 128730876G>C, 30+5542C>G, 32293292G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs13223171 1140913C>T, 1349-47868C>T, 146949365C>T, 7544988C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs1458038 5712444C>T, 81164723C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs16849146 14114343T>C, 73903676T>C
T > C
Not Available
No VIP available CA VA
rs16960228 1854+3730G>A, 30062979G>A, 494902G>A, 64788827G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs17010902 127215318A>G, 51763039A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs17137967 -21-7359A>G, -22+3098A>G, 128717518T>C, 24751A>G, 31-7359A>G, 32279934T>C
T > C
Intronic
rs1799752 16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 26840042_26840043insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, ACE D/I
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
Intronic
No VIP available No Clinical Annotations available VA
rs1799983 11291734T>G, 12965T>G, 150696111T>G, 894T>G, Asp298Glu, NOS3:894G>T
T > G
Missense
Asp298Glu
No VIP available No Clinical Annotations available VA
rs1799998 -344T>C, 143999600A>G, 4660T>C, 57273149A>G, CYP11B2 ¿344T/C
A > G
5' Flanking
rs1801253 115805056G>C, 1165C>G, 1165G>C, 6251G>C, 66609520G>C, ADRB1:389Arg>Gly, ADRB1:Arg389Gly, Gly389Arg
G > C
Missense
Gly389Arg
No VIP available No Clinical Annotations available VA
rs2106809 13499823A>G, 15618061A>G, 186+788T>C, 7132T>C
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs2107614 45855T>C, 760-19729T>C, 843079T>C, 903079T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs221903 52600208T>C, 71600208T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs2230345 121086097A>T, 122A>T, 71890561A>T, Gln41Leu
A > T
Missense
Gln41Leu
No VIP available No Clinical Annotations available VA
rs2269879 2134896T>C, 2194896T>C, 35749T>C, 651+320T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs2273359 27758194C>G, 340+184C>G, 57562102C>G
C > G
Intronic
No VIP available No Clinical Annotations available VA
rs2277869 1016910T>C, 159686T>C, 5900-103T>C, 6644-103T>C, 7400-103T>C, 7424-103T>C, 956910T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs2286007 114067C>T, 1994C>T, 911291C>T, 971291C>T, Thr665Ile
C > T
Missense
Thr665Ile
No VIP available CA VA
rs238 27950808A>G, 98786276A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs2400707 -1343A>G, 148205052A>G, 3897A>G, 9367979A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2432742 113825058A>G, 1548-12555T>C, 1740-12555T>C, 1860-12555T>C, 27098607A>G
A > G
Intronic
No VIP available CA VA
rs2776546 68628156C>A, 87628156C>A
C > A
Not Available
No VIP available No Clinical Annotations available VA
rs2846680 -192+6573T>G, -192+7223T>G, -22+7223T>G, 12424T>G, 128729845A>C, 30+6573T>G, 32292261A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs292449 -241-17578G>C, -242+6092G>C, -300G>C, 123-17578G>C, 188472G>C, 3685945G>C, 55895081G>C, 99-17578G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs3184504 111884608T>C, 2461138T>C, 45857T>C, 784T>C, SH2B3: 784T>C, Trp262Arg, W262R
T > C
Missense
Trp262Arg
No VIP available No Clinical Annotations available VA
rs3758785 387+1888T>C, 39437934A>G, 94132139A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4074471 25899350T>G, 25959350T>G, 735-187583T>G
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs4132670 114767771G>A, 381+56405G>A, 382-32013G>A, 451-32013G>A, 62763G>A, 65572235G>A
G > A
Intronic
No VIP available CA VA
rs4149601 -315-16229G>A, -326G>A, -404G>A, 110182G>A, 24G>A, 3607655G>A, 49-16229G>A, 55816791G>A, Gln8=
G > A
5' UTR
Gln8Gln
No VIP available No Clinical Annotations available VA
rs4376293 162589858T>C, 7401131T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs4506565 114756041A>T, 381+44675A>T, 382-43743A>T, 450+31658A>T, 51033A>T, 65560505A>T
A > T
Intronic
No VIP available No Clinical Annotations available VA
rs4551053 157838542G>A, 2649815G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs4686799 186451236T>C, 21139T>C, 822+773T>C, 92946382T>C, 930+773T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs4784333 1364+1067C>G, 236214C>G, 53969088C>G, 7583287C>G
C > G
Intronic
No VIP available CA VA
rs4791040 1854+2476T>C, 30061725T>C, 493648T>C, 64787573T>C
T > C
Intronic
No VIP available CA VA
rs4815273 2440871C>T, 2500871C>T
C > T
Not Available
No VIP available CA VA
rs4961 1378G>T, 1428061G>T, 2906707G>T, 66124G>T, ADD1:Gly460Trp, Gly460Trp, alpha-adducin Gly460Trp, rs4961 G>T
G > T
Missense
Gly460Trp
No VIP available No Clinical Annotations available VA
rs5030062 186454180A>C, 24083A>C, 823-2708A>C, 92949326A>C, 931-2708A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs5051 -44G>A, 230849872C>T, 24367651C>T, 5465G>A, AGT G(-6)A
C > T
5' UTR
No VIP available No Clinical Annotations available VA
rs5186 *86A>C, 148459988A>C, 49331A>C, 54955134A>C, AGTR1:1166A/C, AGTR1:1166A>C, AGTR1:116A>C, AGTR1:A1166C, AT, R A1166C, angiotensin II type 1 receptor A1166C
A > C
3' UTR
No VIP available No Clinical Annotations available VA
rs5443 10501C>T, 47295C>T, 6894875C>T, 6954875C>T, 825C>T, GNB3:825C>T, GNB3:Ser275Ser, Ser275=
C > T
Synonymous
Ser275Ser
No VIP available No Clinical Annotations available VA
rs5723 1947C>G, 23166787C>G, 23226787C>G, 37748C>G, Leu649=
C > G
Synonymous
Leu649Leu
No VIP available No Clinical Annotations available VA
rs5729 *606T>A, 23167396T>A, 23227396T>A, 38357T>A
T > A
3' UTR
No VIP available No Clinical Annotations available VA
rs59172778 1013T>C, 1070T>C, 128709126A>G, 32271542A>G, 33143T>C, Met338Thr, Met357Thr
A > G
Missense
Met357Thr
No VIP available No Clinical Annotations available VA
rs6083538 2442740C>T, 2502740C>T
C > T
Not Available
No VIP available CA VA
rs658903 -191-7282A>T, -22+9001A>T, 128728067T>A, 14202A>T, 30+8351A>T, 32290483T>A
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs675388 *1011C>T, 128708009G>A, 32270425G>A, 34260C>T
G > A
3' UTR
No VIP available No Clinical Annotations available VA
rs689979 1980+378T>C, 27883205T>C, 98718673T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs6947309 -26+10567C>T, 139035830C>T, 15706C>T, 259+5463C>T, 77068673C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs698078 1018-84A>G, 1126-84A>G, 186459227A>G, 29130A>G, 92954373A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs7247267 16106971G>T, 43838753G>T
G > T
Not Available
No VIP available CA VA
rs7297610 31967330C>T, 69824024C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs75982813 -885A>G, 3501872A>G, 4399A>G, 55711008A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs7917983 114732882T>C, 27874T>C, 381+21516T>C, 450+8499T>C, 65537346T>C
T > C
Intronic
No VIP available CA VA
rs880054 131334C>T, 2370+1031C>T, 2374-181C>T, 3612+1031C>T, 3867+1031C>T, 928558C>T, 988558C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs9933692 25898240G>A, 25958240G>A, 735-188693G>A
G > A
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Dihydrochlorothiazid
  • Dihydrochlorothiazide
  • Dihydrochlorothiazidum
  • Dihydrochlorurit
  • Dihydrochlorurite
  • Dihydroxychlorothiazidum
  • HCT
  • HCTZ
  • HCZ
  • Hydrochlorothiazid
  • Hydrochlorthiazide
Trade Names
  • Acuretic
  • Aldoril
  • Apresazide
  • Aquarills
  • Aquarius
  • Bremil
  • Caplaril
  • Capozide
  • Chlorosulthiadil
  • Chlorzide
  • Cidrex
  • Dichlorosal
  • Dichlorotride
  • Dichlotiazid
  • Dichlotride
  • Diclotride
  • Dicyclotride
  • Direma
  • Disalunil
  • Diu-Melusin
  • Drenol
  • Esidrex
  • Esimil
  • Fluvin
  • Hidril
  • Hidrochlortiazid
  • Hidroronol
  • Hidrotiazida
  • Hydril
  • Hydro-Aquil
  • Hydro-Diuril
  • HydroDIURIL
  • Hydrodiuretic
  • Hydropres
  • Hydrosaluric
  • Hydrothide
  • Hydrozide
  • Hypothiazid
  • Hypothiazide
  • Idrotiazide
  • Ivaugan
  • Jen-Diril
  • Lotensin Hct
  • Maschitt
  • Megadiuril
  • Microzide
  • Moduretic
  • Nefrix
  • Neo-Codema
  • Neoflumen
  • Newtolide
  • Panurin
  • Ro-Hydrazide
  • Servithiazid
  • Thiaretic
  • Thiuretic
  • Thlaretic
  • Timolide
  • Urodiazin
  • Vetidrex
  • Ziac
Brand Mixture Names

PharmGKB Accession Id:
PA449899

Description

A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.

Source: Drug Bank

Indication

For the treatment of high blood pressure and management of edema.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.

Source: Drug Bank

Pharmacology

Thiazides such as hydrochlorothiazide promote water loss from the body (diuretics). They inhibit Na +/Cl - reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Increase potassium intake; add a banana or orange juice; unless instructed otherwise.|Avoid excess salt/sodium unless otherwise instructed by your physician.|Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.|Avoid natural licorice.|Take with food.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hydrochlorothiazide is not metabolized.

Source: Drug Bank

Protein Binding

67.9%

Source: Drug Bank

Absorption

50-60%

Source: Drug Bank

Half-Life

5.6 and 14.8 hours

Source: Drug Bank

Toxicity

The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

Source: Drug Bank

Route of Elimination

Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Source: Drug Bank

Chemical Properties

Chemical Formula

C7H8ClN3O4S2

Source: Drug Bank

Isomeric SMILES

c1c2c(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)NCN2

Source: OpenEye

Canonical SMILES

NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1

Source: Drug Bank

Average Molecular Weight

297.739

Source: Drug Bank

Monoisotopic Molecular Weight

296.964474846

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
CA1 (source: Drug Bank)
CA12 (source: Drug Bank)
CA2 (source: Drug Bank)
CA4 (source: Drug Bank)
CA9 (source: Drug Bank)
KCNMA1 (source: Drug Bank)
SLC12A3 (source: Drug Bank)

Drug Interactions

Drug Description
hydrochlorothiazide The diuretic increases the adverse effects of amantadine (source: Drug Bank)
hydrochlorothiazide Possible electrolyte variations and arrhythmias (source: Drug Bank)
hydrochlorothiazide Possible electrolyte variations and arrhythmias (source: Drug Bank)
amantadine The diuretic increases the adverse effect of amantadine (source: Drug Bank)
deslanoside Possible electrolyte variations and arrhythmias (source: Drug Bank)
diazoxide Significant hyperglycemic effect (source: Drug Bank)
diazoxide Significant hyperglycemic effect (source: Drug Bank)
digitoxin Possible electrolyte variations and arrhythmias (source: Drug Bank)
digitoxin Possible electrolyte variations and arrhythmias (source: Drug Bank)
digoxin Possible electrolyte variations and arrhythmias (source: Drug Bank)
digoxin Possible electrolyte variations and arrhythmias (source: Drug Bank)
dofetilide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
dofetilide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
lithium The thiazide diuretic increases serum levels of lithium (source: Drug Bank)
lithium The thiazide diuretic increases serum levels of lithium (source: Drug Bank)
hydrochlorothiazide The thiazide diuretic increases serum levels of lithium (source: Drug Bank)
hydrochlorothiazide The thiazide diuretic increases serum levels of lithium (source: Drug Bank)
hydrochlorothiazide Tenoxicam may antagonize the blood pressure lowering effect of Hydrochlorothiazide. Monitor for changes in the therapeutic effect of Hydrochlorothiazide if Tenoxicam is initiated, discontinued or dose changed. (source: Drug Bank)
hydrochlorothiazide The thiazide diuretic, Hydrochlorothiazide, may increase the hypotensive effect of Trandolapril. Hydrochlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. (source: Drug Bank)
hydrochlorothiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to hydrochlorothiazide: 49

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. The pharmacogenomics journal. 2014. Del-Aguila J L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project". American journal of medical genetics. Part C, Seminars in medical genetics. 2014. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hydrochlorothiazide-induced hyperuricaemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Journal of internal medicine. 2014. Vandell Alexander G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenetics and genomics. 2013. Karnes Jason H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PROX1 Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment. Pharmacotherapy. 2013. Gong Yan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genomic Association Analysis of Common Variants Influencing Antihypertensive Response to Hydrochlorothiazide. Hypertension. 2013. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. The pharmacogenomics journal. 2013. Del-Aguila J L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of hypertension. 2013. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. PloS one. 2013. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives - Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Circulation. Cardiovascular genetics. 2012. Gong Yan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. The pharmacogenomics journal. 2012. Karnes J H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genomic Association Analysis Identifies Multiple Loci Influencing Antihypertensive Response to an Angiotensin II Receptor Blocker. Hypertension. 2012. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. The pharmacogenomics journal. 2012. Duarte J D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men. Hypertension research : official journal of the Japanese Society of Hypertension. 2012. Donner Kati M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. Journal of translational medicine. 2012. Duarte Julio D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. Journal of translational medicine. 2012. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. American journal of hypertension. 2011. Smith Steven M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics. 2011. Citterio Lorena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in renin predicts the effects of thiazide diuretics. European journal of clinical investigation. 2011. Huang Chin-Chou, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. American journal of hypertension. 2011. Han Yun-Feng, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. Journal of hypertension. 2011. Svensson-Färbom Patrik, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients. Clinical and experimental hypertension (New York, N.Y. : 1993). 2011. Li Yun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenetics and genomics. 2010. Lobmeyer Maximilian T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combination antihypertensive treatment: is initiation order important?. Journal of clinical hypertension (Greenwich, Conn.). 2010. Gums John G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenetics and genomics. 2010. Duarte Julio D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010. Cooper-DeHoff Rhonda M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. Journal of clinical hypertension (Greenwich, Conn.). 2010. Beitelshees Amber L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clinical pharmacology and therapeutics. 2009. Johnson J A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension. 2009. Luo Fang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009. Smith Steven M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study. Physiological genomics. 2009. Barbalic Maja, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. American journal of hypertension. 2009. Suonsyrjä Timo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension. 2008. Manunta Paolo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clinical pharmacology and therapeutics. 2007. Fan X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chinese medical journal. 2007. Jiang Xiao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. European journal of clinical pharmacology. 2006. Vormfelde Stefan Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. American journal of hypertension. 2005. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenetics and genomics. 2005. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertension research : official journal of the Japanese Society of Hypertension. 2004. Matayoshi Tetsutaro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. The pharmacogenomics journal. 2004. Frazier L, et al. PubMed
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. American journal of hypertension. 2003. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension. 2003. Sciarrone Maria Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney international. 2002. Schwartz Gary L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension. 2002. Glorioso Nicola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 2001. Turner S T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension. 1999. Glorioso N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997. Cusi D, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0378-3603-01
DrugBank:
DB00999
KEGG Drug:
D00340
PubChem Compound:
3639
PubChem Substance:
7847406
Drugs Product Database (DPD):
2247386
BindingDB:
13076
Therapeutic Targets Database:
DAP000750
FDA Drug Label at DailyMed:
091691f1-260b-4ae3-9484-a945a905fffd

Clinical Trials

These are trials that mention hydrochlorothiazide and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.